Lilly's Alimta combination cancer therapy fails trial
Sept 6 (Reuters) - Eli Lilly and Co said a late-stage trial testing its lung cancer drug Alimta failed to meet the main study goal of improving overall survival of patients.
Patients on the trial, named Pointbreak, were given either a combination of Alimta and Roche Holding AG's cancer drug Avastin along with chemotherapy, or just Avastin along with chemotherapy drugs.
- Malaysian plane presumed crashed; questions over false IDs |
- Malaysia signals missing plane has crashed; probes false IDs |
- Libya threatens to bomb North Korean tanker if it ships oil from rebel port
- Malaysian jet's disappearance among rarest of aviation disasters